Sentiment-Signal
7,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Unternehmen & Branche
| Name | Vera Therapeutics, Inc. |
|---|---|
| Ticker | VERA |
| CIK | 0001831828 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,58 Mrd. USD |
| Beta | 1,17 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -299,615,000 | -4.66 | 734,733,000 | 604,521,000 | |
| 2025-09-30 | 10-Q | -80,293,000 | -1.26 | 517,503,000 | 398,880,000 | |
| 2025-06-30 | 10-Q | -76,531,000 | -1.20 | 578,528,000 | 468,277,000 | |
| 2025-03-31 | 10-Q | -51,694,000 | -0.81 | 610,167,000 | 534,999,000 | |
| 2024-12-31 | 10-K | -152,148,000 | -2.75 | 655,681,000 | 577,155,000 | |
| 2024-09-30 | 10-Q | -46,632,000 | -0.85 | 368,560,000 | 289,058,000 | |
| 2024-06-30 | 10-Q | -33,708,000 | -0.62 | 397,291,000 | 327,869,000 | |
| 2024-03-31 | 10-Q | -28,383,000 | -0.56 | 419,356,000 | 353,542,000 | |
| 2023-12-31 | 10-K | -95,990,000 | -2.25 | 175,546,000 | 101,685,000 | |
| 2023-09-30 | 10-Q | -20,104,000 | -0.45 | 175,618,000 | 123,707,000 | |
| 2023-06-30 | 10-Q | -20,162,000 | -0.46 | 195,178,000 | 140,523,000 | |
| 2023-03-31 | 10-Q | -30,069,000 | -0.80 | 209,604,000 | 157,709,000 | |
| 2022-12-31 | 10-K | -89,056,000 | -3.35 | 131,435,000 | 76,908,000 | |
| 2022-09-30 | 10-Q | -24,679,000 | -0.91 | 131,370,000 | 105,718,000 | |
| 2022-06-30 | 10-Q | -14,853,000 | -0.55 | 148,782,000 | 121,504,000 | |
| 2022-03-31 | 10-Q | -17,085,000 | -0.71 | 164,974,000 | 134,425,000 | |
| 2021-12-31 | 10-K | -32,609,000 | -2.43 | 83,748,000 | 69,592,000 | |
| 2021-09-30 | 10-Q | -7,611,000 | -0.36 | 91,167,000 | 85,477,000 | |
| 2021-06-30 | 10-Q | -3,437,000 | -0.33 | 97,647,000 | 92,155,000 | |
| 2021-03-31 | 10-Q | -4,714,000 | 51,825,000 | -93,316,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | Fordyce Marshall | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -900 | 45.51 | -40,960.26 | -7,8% | |
| 2026-04-14 | Fordyce Marshall | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -14,130 | 43.66 | -616,985.04 | -117,8% | |
| 2026-04-14 | Fordyce Marshall | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -7,921 | 44.58 | -353,105.51 | -67,4% | |
| 2026-02-23 | JOHNSON DAVID LEE | Officer, Chief Operating Officer | Open Market Sale | -2,579 | 41.98 | -108,276.48 | -20,7% | |
| 2026-02-23 | Brenner Robert | Officer, Chief Medical Officer | Open Market Sale | -2,151 | 41.98 | -90,307.37 | -17,2% | |
| 2026-02-23 | Grant Sean | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -4,949 | 41.98 | -207,778.32 | -39,7% | |
| 2026-02-23 | Turner William D. | Officer, Chief Regulatory Officer | Open Market Sale | -2,187 | 41.98 | -91,818.79 | -17,5% | |
| 2026-02-23 | Skelton Laurence Matthew | Officer, Chief Commercial Officer | Open Market Sale | -1,582 | 41.98 | -66,418.53 | -12,7% | |
| 2026-02-23 | Young Joseph R | Officer, SVP, FINANCE, CHIEF ACCT OFFCR | Open Market Sale | -3,117 | 41.98 | -130,863.82 | -25,0% | |
| 2026-02-23 | Fordyce Marshall | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -16,925 | 41.98 | -710,577.51 | -135,7% | |
| 2025-12-11 | ENRIGHT PATRICK G | Director | Open Market Purchase | 5,882 | 42.50 | 249,985.00 | +47,7% | |
| 2025-11-11 | Young Joseph R | Officer, SVP, FINANCE, CHIEF ACCT OFFCR | Open Market Sale | -15,000 | 29.06 | -435,874.50 | -83,2% | |
| 2025-06-24 | ENRIGHT PATRICK G | Director | Open Market Purchase | 27,071 | 22.35 | 605,082.87 | +115,5% | |
| 2025-06-24 | ENRIGHT PATRICK G | Director | Open Market Purchase | 13,536 | 22.35 | 302,552.61 | +57,8% | |
| 2025-06-23 | ENRIGHT PATRICK G | Director | Open Market Purchase | 69,798 | 20.87 | 1,456,565.60 | +278,1% | |
| 2025-06-23 | ENRIGHT PATRICK G | Director | Open Market Purchase | 139,595 | 20.87 | 2,913,110.34 | +556,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.